Until recently, the main strategy in developing AD drugs was inhibition of AChE activity, but a few years back BChE also appeared in the focus of research since its activity with the progression of AD increased compared to the activity of AChE that significantly decreased with the time [8,9]. Here, BCHE is linked to Alzheimer disease.